Please login to the form below
CALD
This page shows the latest CALD news and features for those working in and with pharma, biotech and healthcare.
bluebird bio reveals plans to launch two gene therapies
Eli-cel is under priority review for the treatment of early active cerebral adrenoleukodystrophy (CALD) in patients under the age of 18 who do not have an available and willing matched ... CALD is a rare neurodegenerative disease that primarily affects
Latest news
-
Gene therapy company bluebird bio quits Europe
The announcement comes after its trial in the rare neurological condition cerebral adrenoleukodystrophy (CALD) was halted after a boy was diagnosed with myelodysplastic syndrome, a condition that can develop into leukaemia.
-
EU approves bluebird bio’s CALD gene therapy Skysona
The European Commission (EC) has approved bluebird bio’s gene therapy Skysona for the rare inherited neurological disease cerebral adrenoleukodystrophy (CALD). ... MFDs are the six severe disabilities commonly attributed to CALD, which have the most
-
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
bluebird bio’s cerebral adrenoleukodystrophy (CALD) gene therapy Skysona has moved closer towards EU approval after gaining a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for ... MFDs are the six severe
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
bluebird bio has revealed new data from its clinical development programme for Lenti-D gene therapy in cerebral adrenoleukodystrophy (CALD). ... In October 2020, the European Medicines Agency (EMA) accepted a marketing authorisation application (MAA) for
-
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
CALD mid-year and the planned US filings for beta-thalassemia and CALD later in the year,” said Nick Leschly, chief executive officer of bluebird.
More from news
Approximately 6 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder.
-
Bluebird Bio: on the cusp of a gene therapy revolution
Bluebird’s four breakthrough candidates. In addition to the two LentiGlobin-based treatments, the company also has its Lenti-D product for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
